FDA announces public meeting on abuse-deterrent opioids

be pursued during the meeting and a summation of the FDA’s standard for success when it comes to abuse-deterrent opioid formulations.

In order to qualify, the formulation must meet two standards. The first requires that, when used as labeled, the medication delivers a dose of the opioid that is effective and consistent. The second standard dictates that the drugs have properties that can significantly reduce the potential for abuse.

The paper also highlights where the FDA hopes the program will head in the future, eventually culminating in the availability of abuse-deterrent opioid formulations for all major opioids.

A spokesperson for the FDA declined a request for further comment on the upcoming meeting.

Article Name
FDA announces public meeting on abuse-deterrent opioids
Food and Drug Administration Commissioner Scott Gottlieb has announced that the FDA will host a two-day public meeting to consider whether or not abuse-deterrent formulations are effectively preventing substance abuse.
Topher Avery
Publisher Name
Addiction Now